Metoprolol Carinopharm (Metoprolol Tartrate)

Metoprolol Tartrate is a selective β1‑adrenergic receptor antagonist. By blocking these receptors in the heart, it reduces the effects of adrenaline, leading to decreased heart rate, contractility, and cardiac output, which in turn lowers blood pressure and myocardial oxygen consumption.

The appropriate dose of Metoprolol Carinopharm is determined by the prescribing clinician based on the patient’s clinical condition, response to therapy, and any relevant comorbidities. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety of Metoprolol Carinopharm in pregnancy or lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Metoprolol Carinopharm is a cardio‑selective β1‑blocker, offering a favorable profile for patients where bronchial β2 blockade is undesirable. Compared with non‑selective beta blockers, it provides similar antihypertensive and anti‑anginal effects with reduced risk of bronchospasm, making it a preferred choice in patients with respiratory concerns.

Metoprolol Carinopharm should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Maintaining the cold‑chain ensures the stability and potency of the injectable solution.

Metoprolol Carinopharm is supplied as an injectable solution for intravenous use. It is administered by a healthcare professional, typically as a slow IV infusion or bolus, according to the prescriber’s dosing instructions and patient monitoring protocols.

Serious risks include severe bradycardia, heart block, marked hypotension, acute heart failure exacerbation, bronchospasm in susceptible individuals, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for these events, especially during dose initiation or escalation.

Metoprolol Carinopharm is contraindicated in patients with known hypersensitivity to metoprolol or any component of the formulation, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and patients in cardiogenic shock. Caution is also advised for individuals with uncontrolled asthma or severe peripheral vascular disease.